The strategic goals of Binnopharm Group are:
to become one of the leaders in the Russian pharmaceutical market,
to enhance the sales development and expand its presence in foreign markets,
to improve the company’s operational efficiency and investment appeal.
Alium was created through the merger of Binnopharm, a pharmaceuticals company established by Sistema in 2006, and OBL Pharm, one of the leading Russian pharmaceutical companies.
JSC Binnopharm is one of Russia's largest full-cycle biopharmaceutical companies producing biotechnological drugs, including the COVID0-19 and hepatitis B vaccines, a line of pulmonology and neurology drugs, infusion solutions, and anti-viral and immunomodulating drugs. Modern production facilities allow the company to produce a wide range of dosage forms, including tablets, capsules, ampoules, suppositories, syringes and solutions. Binnopharm operates Russia's largest GMP facilities for the production of vaccines in ampoules (producing as many as 80 mln ampoules per year) and a unique, fully equipped quality control laboratory.
OBL Pharm is an asset Sistema acquired in 2019 as a part of an investment consortium. This is one of the leading Russian pharmaceutical companies that since 1994 develops, manufactures and promotes the latest high-quality medications in compliance with GMP and ISO standards. It produces over 150 prescription and OTC drugs in several therapeutic areas: gastroenterology, cardiology, phlebology, pain relief, insomnia, neurology, male health and others. The company's portfolio includes both innovative products and generics.
In August 2019, Sistema, together with VTB Group, acquired a 46.5% equity stake in Sintez. In May 2020, Sistema and VTB Group increased their stake in Sintez to 56.2%. In March 2021 Sistema acquired 32.4% of Sintez from National Immunobiological Company (Nacimbio). In May Binnopharm Group has increased its stake in OJSC Sintez to 88.6%.
The Group’s revenue increased by 30.1% to RUB 21.4 billion in 2020, while the market grew by 13.8% over the same period.
Thanks to the control of purchase prices, including prices for imported substances, and administrative costs, as well as optimization of sales plans in connection with changed consumer demand amid the pandemic, the Group’s OIBDA grew by 38.6% YoY.